Biopharma Stocks Stall After Earnings, Lag Over 52 Weeks

It is hard to forecast with the current choppy setting in the biopharma sector, but assuming that the COVID-19 vaccinations are on track in the U.S., financial results should improve for most large-cap biopharmas.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.